Jackson Creek Investment Advisors LLC Makes New Investment in Omnicell, Inc. $OMCL

Jackson Creek Investment Advisors LLC acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 4th quarter, Holdings Channel.com reports. The firm acquired 44,627 shares of the company’s stock, valued at approximately $2,022,000.

Other hedge funds have also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its holdings in shares of Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after purchasing an additional 117,556 shares during the period. Dana Investment Advisors Inc. bought a new position in shares of Omnicell during the fourth quarter worth approximately $3,445,000. Dynamic Technology Lab Private Ltd increased its holdings in shares of Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after purchasing an additional 24,738 shares during the period. Peregrine Capital Management LLC bought a new position in shares of Omnicell during the fourth quarter worth approximately $4,804,000. Finally, AlphaQuest LLC increased its holdings in shares of Omnicell by 388.4% during the third quarter. AlphaQuest LLC now owns 24,231 shares of the company’s stock worth $738,000 after purchasing an additional 19,270 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on OMCL. KeyCorp raised their target price on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Wells Fargo & Company raised their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Finally, Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $59.86.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $44.10 on Wednesday. The company’s 50 day simple moving average is $38.42 and its 200 day simple moving average is $40.96. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 100.23, a price-to-earnings-growth ratio of 1.15 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. Omnicell, Inc. has a 1 year low of $26.84 and a 1 year high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period last year, the firm posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, research analysts predict that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the transaction, the executive vice president directly owned 96,717 shares in the company, valued at $3,355,112.73. This trade represents a 7.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 15,520 shares of company stock worth $607,610 over the last three months. 2.92% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.